Showing results (61-70 of 77) with videos related to

Sort By:
Pageof 8
The Mental Health Clinician|December 22, 2023
Exploring real-world symptom impact and improvement in well-being domains for tardive dyskinesia in VMAT2 inhibitor-treated patients via clinician survey and chart reviewJonathan M Meyer, Craig Chepke, Rimal B Bera, et al.
CNS Spectrums|April 18, 2013
“Meta-guidelines” for the management of patients with schizophreniaStephen M Stahl, Debbi A Morrissette, Leslie Citrome, et al.
Schizophrenia Research|September 3, 2005
Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES IIIJoseph P McEvoy, Jonathan M Meyer, Donald C Goff, et al.
Biological Psychiatry|July 31, 2009
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness studyJonathan M Meyer, Joseph P McEvoy, Vicki G Davis, et al.
CNS Drugs|March 19, 2024
An Evidence-Based Update on Anticholinergic Use for Drug-Induced Movement DisordersNora Vanegas-Arroyave, Stanley N Caroff, Leslie Citrome, et al.
Schizophrenia Research|August 30, 2005
The Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE) Schizophrenia Trial: clinical comparison of subgroups with and without the metabolic syndromeJonathan M Meyer, Henry A Nasrallah, Joseph P McEvoy, et al.
Schizophrenia Research|November 1, 2008
Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapineJohn W Newcomer, Jonathan M Meyer, Ross A Baker, et al.
Schizophrenia Research|October 4, 2005
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controlsDonald C Goff, Lisa M Sullivan, Joseph P McEvoy, et al.
Schizophrenia Research|June 7, 2008
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1Jonathan M Meyer, Vicki G Davis, Joseph P McEvoy, et al.
Schizophrenia Research|September 9, 2008
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia studyGail L Daumit, Donald C Goff, Jonathan M Meyer, et al.
Pageof 8